Eiger receives European approval for Zokinvy® (lonafarnib) for Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies, collectively known as progeria, making it the first and only treatment approved in Europe to treat this rare, rapid-aging disease. Eiger’s mission is to bring innovative medicines to underserved patients around the world. This approval brings us a step closer to achieving that goal. For more information go to Zokinvy.eu


Click to read press release


About Us

Developing and commercializing first-in-class, well-characterized drugs for life-threatening, rare and ultra-rare diseases with high unmet medical needs and no approved therapies.